ERCC1、BRCA1基因蛋白在晚期NSCLC中的表达及其临床意义  

Expression of ERCC1 and BRCA1 in advanced Non small cell lung cancer and its clinical significance

作　　者：陈茹[1] 陈锐[1] 单利[2] 

机构地区：[1]新疆维吾尔自治区人民医院肿瘤内科 [2]新疆医科大学附属肿瘤医院内一科,乌鲁木齐830000

出　　处：《新疆医科大学学报》2011年第12期1362-1365,共4页Journal of Xinjiang Medical University

基　　金：新疆维吾尔自治区科技支疆项目(编号:201191246)

摘　　要：目的探讨ERCC1和BRCA1基因蛋白在晚期非小细胞肺癌(NSCLC)中的表达及其与铂类化疗近期疗效之间的关系。方法采用免疫组化法对152例晚期非小细胞肺癌中ERCC1和BRCA1基因蛋白的表达进行检测,并通过Lgistic回归的方法对ERCC1、BRCC1基因蛋白表达与各临床特征(性别、年龄、是否吸烟、临床分期、病理类型)及晚期非小细胞肺癌含铂化疗方案的近期有效率进行分析。结果 ERCC1和BRCA1基因蛋白的表达与各临床特征之间均无相关性(P>0.05),ERCCl基因蛋白表达阴性者,应用含铂方案化疗,其近期疗效明显高于ERCCl基因蛋白表达阳性的非小细胞肺癌患者(P<0.05),BRCA1基因蛋白的表达与含铂化疗近期疗效无关(P>0.05)。结论 ERCC1基因蛋白可预测非小细胞肺癌对含铂联合化疗方案的敏感性。Objective To investigate the Expression of ERCC1,BRCA1 and the correlation with platinum-based chemotherapy clinical efficacy in the advanced non-small cell lung cancer.Methods The expression of ERCC1,BRCA1 in 152 patients with advanced non-small cell lung cancer was detected by immunohistochemical technique.Retrospective analysis Lgistic regression equation was used to analyze expression of ERCC1, BRCC1 and the clinical characteristics （sex, age, smoking, clinical stage, pathological type） and advanced non-small cell lung cancer with platinum-based chemotherapy in short-term therapy.Results There were no differences between different pathological classification and clinical TNM stages, age ,sexuality, smoke state（P 〉0.05）.The patients with negative ERCCl expression, after application of platinum-based chemotherapy, its short term effect was significantly higher than short-term effect of non-small cell lung cancer with positive ERCCl expression （P〈0.05）,The expression of BRCAl was not related with clinical efficacy（P 〉0.05）.Conclusion The results suggest that the expression of ERCC1 could predict the sensitivity in advanced non-small cell lung cancer with paltinum-based chemotherapy.

关 键 词：ERCC1 BRCA1 晚期非小细胞肺癌 化疗 

分 类 号：R734.2[医药卫生—肿瘤]